[Diagnosis, pathogenesis and latest therapy in portal hypertension].
Kokubu
Shigehiro
S
Department of Gastroenterology, Juntendo University School of Medicine Nerima Hospital.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000990:Antithrombin III / Q000627:therapeutic use; D021721:Balloon Occlusion; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004621:Embolization, Therapeutic / Q000379:methods; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D006975:Hypertension, Portal / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D013157:Splenic Artery
D047228:Angiotensin II Type 1 Receptor Blockers; D000990:Antithrombin III; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006497:Heparan Sulfate; C035838:danaparoid